Mechanism of action

The TB-500 fragment Ac-LKKTETQ corresponds to an actin-binding region of thymosin beta-4, but sequence overlap does not establish equivalence to the complete peptide. Most mechanistic findings cited here concern full-length Tβ4, whose interaction with monomeric G-actin regulates actin polymerization dynamics. In cell and animal models, full-length Tβ4 has been associated with endothelial-cell, keratinocyte and fibroblast migration, activation of the ILK-PI3K-Akt survival axis, angiogenesis and extracellular-matrix remodeling. Bock-Marquette et al. (Nature 2004) examined cardiac repair and survival pathways; Smart et al. (Nature 2011) investigated Wt1-positive epicardial progenitor cells in the adult mouse heart after injury. These observations provide context for the parent peptide. They do not automatically demonstrate the same actin interaction, downstream mechanism or tissue effect for isolated Ac-LKKTETQ. The Ho et al. (2012) study identifies the acetylated fragment and metabolites in equine urine and plasma using liquid chromatography-mass spectrometry; analytical detectability is not evidence of human therapeutic action.

State of evidence

Evidence must be separated by molecular identity. The primary TB-500 study by Ho et al. (J Chromatogr A 2012) concerns equine doping-control analysis of N-acetylated LKKTETQ and its metabolites. It is not a clinical efficacy study. The tissue-repair work commonly cited alongside TB-500 predominantly concerns full-length 43-amino-acid Tβ4: cell and animal studies describe actin-related functions, wound repair and cardiac models (Bock-Marquette et al., 2004; Smart et al., 2011; Treadwell et al., 2012). Early human findings likewise concern different preparations of full-length Tβ4. Ruff et al. (2010) studied intravenous pharmaceutical Tβ4 in a randomized, placebo-controlled phase 1 safety and pharmacokinetic trial. The RGN-259 eye-drop trial in neurotrophic keratopathy enrolled 18 patients and did not significantly meet its primary endpoint (Sosne et al., 2023). Neither intravenous full-length-peptide findings nor a topical eye-drop trial establishes clinical efficacy or safety of the TB-500 fragment. The cited evidence also does not support a general seven-day fragment half-life or determine the authorization status of a particular research product.

Questions about the research

What is TB-500 investigated for in research?

The Ac-LKKTETQ fragment identified as TB-500 in primary analytical literature is studied in doping control, including detection of the fragment and metabolites in equine samples. Research on wound healing, cell migration and cardiac repair mainly concerns its parent peptide, full-length thymosin beta-4. Those molecular identities must not be used interchangeably.

What is the state of the evidence on TB-500?

The fragment-specific source concerns analytical detection rather than human therapeutic outcomes. Preclinical tissue-repair findings, an early intravenous human trial and the small RGN-259 eye-drop trial concern full-length Tβ4 or its pharmaceutical formulations. The eye-drop trial did not significantly meet its primary endpoint. None of these findings establishes clinical benefit, general safety or a seven-day half-life for Ac-LKKTETQ research material.

Sources

1. Bock-Marquette et al., Nature 2004 (ILK/PI3K-Akt axis)DOI: 10.1038/nature03000PMID: 15565145
2. Treadwell et al., Ann N Y Acad Sci 2012DOI: 10.1111/j.1749-6632.2012.06717.xPMID: 23050815
3. Smart et al., Nature 2011DOI: 10.1038/nature10188PMID: 21654746
4. Ruff et al., Ann N Y Acad Sci 2010DOI: 10.1111/j.1749-6632.2010.05474.xPMID: 20536472
5. Sosne et al., Int J Mol Sci 2023DOI: 10.3390/ijms24010554PMID: 36613994
6. Ho et al., J Chromatogr A 2012DOI: 10.1016/j.chroma.2012.09.043PMID: 23084823

Mechanism of action

The TB-500 fragment Ac-LKKTETQ corresponds to an actin-binding region of thymosin beta-4, but sequence overlap does not establish equivalence to the complete peptide. Most mechanistic findings cited here concern full-length Tβ4, whose interaction with monomeric G-actin regulates actin polymerization dynamics. In cell and animal models, full-length Tβ4 has been associated with endothelial-cell, keratinocyte and fibroblast migration, activation of the ILK-PI3K-Akt survival axis, angiogenesis and extracellular-matrix remodeling. Bock-Marquette et al. (Nature 2004) examined cardiac repair and survival pathways; Smart et al. (Nature 2011) investigated Wt1-positive epicardial progenitor cells in the adult mouse heart after injury. These observations provide context for the parent peptide. They do not automatically demonstrate the same actin interaction, downstream mechanism or tissue effect for isolated Ac-LKKTETQ. The Ho et al. (2012) study identifies the acetylated fragment and metabolites in equine urine and plasma using liquid chromatography-mass spectrometry; analytical detectability is not evidence of human therapeutic action.

State of evidence

Evidence must be separated by molecular identity. The primary TB-500 study by Ho et al. (J Chromatogr A 2012) concerns equine doping-control analysis of N-acetylated LKKTETQ and its metabolites. It is not a clinical efficacy study. The tissue-repair work commonly cited alongside TB-500 predominantly concerns full-length 43-amino-acid Tβ4: cell and animal studies describe actin-related functions, wound repair and cardiac models (Bock-Marquette et al., 2004; Smart et al., 2011; Treadwell et al., 2012). Early human findings likewise concern different preparations of full-length Tβ4. Ruff et al. (2010) studied intravenous pharmaceutical Tβ4 in a randomized, placebo-controlled phase 1 safety and pharmacokinetic trial. The RGN-259 eye-drop trial in neurotrophic keratopathy enrolled 18 patients and did not significantly meet its primary endpoint (Sosne et al., 2023). Neither intravenous full-length-peptide findings nor a topical eye-drop trial establishes clinical efficacy or safety of the TB-500 fragment. The cited evidence also does not support a general seven-day fragment half-life or determine the authorization status of a particular research product.

Questions about the research

What is TB-500 investigated for in research?

The Ac-LKKTETQ fragment identified as TB-500 in primary analytical literature is studied in doping control, including detection of the fragment and metabolites in equine samples. Research on wound healing, cell migration and cardiac repair mainly concerns its parent peptide, full-length thymosin beta-4. Those molecular identities must not be used interchangeably.

What is the state of the evidence on TB-500?

The fragment-specific source concerns analytical detection rather than human therapeutic outcomes. Preclinical tissue-repair findings, an early intravenous human trial and the small RGN-259 eye-drop trial concern full-length Tβ4 or its pharmaceutical formulations. The eye-drop trial did not significantly meet its primary endpoint. None of these findings establishes clinical benefit, general safety or a seven-day half-life for Ac-LKKTETQ research material.

Sources

1. Bock-Marquette et al., Nature 2004 (ILK/PI3K-Akt axis)DOI: 10.1038/nature03000PMID: 15565145
2. Treadwell et al., Ann N Y Acad Sci 2012DOI: 10.1111/j.1749-6632.2012.06717.xPMID: 23050815
3. Smart et al., Nature 2011DOI: 10.1038/nature10188PMID: 21654746
4. Ruff et al., Ann N Y Acad Sci 2010DOI: 10.1111/j.1749-6632.2010.05474.xPMID: 20536472
5. Sosne et al., Int J Mol Sci 2023DOI: 10.3390/ijms24010554PMID: 36613994
6. Ho et al., J Chromatogr A 2012DOI: 10.1016/j.chroma.2012.09.043PMID: 23084823